Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/20.500.12008/54237

Título:

Genomic insights into Respiratory Syncytial Virus circulation patterns and neutralization by Anti-F Monoclonal Antibodies in Panama (2018–2024)

Otros títulos:

Coordinador:

Director:

Compilador:

Autor:

Franco, Danilo
Goya, Stephanie
Martínez, Alexander
Mas, Vicente
Moreno, Brechla
Valdespino, Elimelec
Gaitán, Melissa
Sáenz, Lisseth
González, Claudia
Moreno, Ambar
Capitan-Barrios, Zeuz
Carrera, Jean Paul
López-Vergès, Sandra
Pascale, Juan Miguel
Moltó, Yadira
Moreno, Lourdes
Rizo, Belmaris
Urriola, Enrique
Delgado, Teresa
Iglesias-Caballero, María
Casas, Inmaculada
Das, S.
Arbiza, Juan
Delfraro Vázquez, Adriana Beatriz
Ábrego Sánchez, Leyda E.

Tutor:

Tipo de documento:

Artículo

Editor:

Palabras clave:

Lineages
Nirsevimab
Respiratory Syncytial Virus

Descriptores:

Año de publicación:

2025

Contenido:

Resumen:

Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections and hospitalization in infants and children. Whole genome sequencing (WGS) plays a critical role in understanding the evolution and epidemiology of RSV. Limited studies have been conducted in Central America and the Caribbean, and none have specifically focused on lineages involved in recent outbreaks. Furthermore, no assays currently exist to evaluate the sensitivity of the RSV fusion protein to monoclonal antibodies. Methods: In Panama, an epidemiological surveillance system tracks RSV activity through the collection of nasopharyngeal samples from patients with acute respiratory infections. Between January 2018 and July 2024, 303 RSV-positive samples were analyzed by RT-qPCR. RSV-B was the dominant subgroup in 2018, but following years had alternating dominance between RSV-A and RSV-B. Of the 303 samples, 115 underwent WGS. Additionally, neutralization assays were done using different Anti-F Monoclonal Antibodies. Results: In RSV-A, 11 lineages were identified, with 3 to 5 cocirculating during each annual outbreak, and a shift in predominance from A.D.1 (2019) to A.D.5.2 (2023–2024). In RSV-B, two lineages circulated: B.D.4.1.1 (2018–2020) and its descendant B.D.E.1, which predominated from 2021 onward. Several monoclonal antibodies, including nirsevimab's precursor MEDI8897*, effectively neutralized the RSV strains in neutralization assays. Conclusions: Although Panama has not yet implemented a preventive therapy for RSV, this step could modify outbreak dynamics. The findings from this study provide a baseline reference prior to the implementation of preventive therapies against RSV in Panama and the region, facilitating the assessment of potential changes in the evolutionary dynamics of the virus.

Descripción:

metadata.articulos.dc.description.uri:

Editorial:

Wiley

EN:

Influenza and Other Respiratory Viruses, 2025, 19(10): e70173.

Financiadores:

Citación:

Franco, D, Goya, S, Martínez, A [y otros autores]. "Genomic insights into Respiratory Syncytial Virus circulation patterns and neutralization by Anti-F Monoclonal Antibodies in Panama (2018–2024)". Influenza and Other Respiratory Viruses. [en línea] 2025, 19(10): e70173. 12 h. DOI: 10.1111/irv.70173

Citación:

metadata.articulos.cc.license.name:

ISBN:

e-ISBN:

ISSN:

1750-2659

ISMN:

Otros identificadores:

Cobertura geográfica:

Cobertura temporal:

Departamento académico:

Grupo de investigación:

Licencia:

Licencia Creative Commons Atribución (CC - By 4.0)

Colecciones:

Publicaciones académicas y científicas
FicherosDescripciónTamañoFormato
10.1111.irv.70173.pdf — 5.42 MB Adobe PDF
Mostrar el registro Dublin Core completo del ítem